The Pharmaceutical Benefits Advisory Committee (PBAC) has three (3) main cycles per year where it considers applications for funding of new medicines and vaccines. For most items on a meeting agenda, there is an eight (8) week consultation period. 

Learn more about the PBAC and the PBS and stay in touch by subscribing to the PBS news.

Open PBAC consultations for feedback

  • Public consultation on items to be considered by the PBAC (March 2024)

    Public consultation on items to be considered by the PBAC (March 2024)

    Consultation has opened for the March 2024 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence...

    Closed 31 January 2024

  • Public consultation on items to be considered by the PBAC (July 2024)

    Public consultation on items to be considered by the PBAC (July 2024)

    Consultation has opened for the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented...

    Closes 29 May 2024